EMTEC
Desconocido
DISCOvERIE: Development dIagnostic and prevention of gender related Somatic and mental COmorbitiEs in iRritable...
EMERGENTEC BIODEVELOPMENT GMBH
participó en un
H2020:
H2020-SC1-BHC-2018-2020
Mental (anxiety and depression) and non-mental (fibromyalgia and chronic fatigue syndrome) comorbidities are highly prevalent in irritable b...
2019-12-13 - 2024-12-31 | Financiado
2019-12-13 - 2024-12-31 | Financiado
DC-ren: Drug combinations for rewriting trajectories of renal pathologies in type II diabetes DC ren
EMERGENTEC BIODEVELOPMENT GMBH
participó en un
H2020:
H2020-SC1-BHC-2018-2020
Diabetic Kidney Disease (DKD) is highly prevalent in type 2 diabetes, with major impact on patients and healthcare systems. The complex diso...
2019-12-13 - 2024-12-31 | Financiado
2019-12-13 - 2024-12-31 | Financiado
PRETREAT: PRoteome based assessment of vascular disease for the Establishment of a Translational REsearch plAT...
EMERGENTEC BIODEVELOPMENT GMBH
participó en un
H2020:
H2020-MSCA-RISE-2015
Cardiovascular disease (VD) is the leading cause of mortality and morbidity in Europe and worldwide. The objective of the PRETREAT consortiu...
2015-10-13 - 2019-12-31 | Financiado
2015-10-13 - 2019-12-31 | Financiado
SYSKID: Systems biology towards novel chronic kidney disease diagnosis and treatment
EMERGENTEC BIODEVELOPMENT GMBH
tramitó un
FP7:
Chronic kidney disease (CKD) affects up to 10% of the population. Besides eventual progression towards end stage renal disease CKD impacts t...
Financiado
Financiado
EU-MASCARA: Markers for Sub Clinical Cardiovascular Risk Assessemnt
EMERGENTEC BIODEVELOPMENT GMBH
participó en un
FP7:
EU-MASCARA is a collaborative project that aims to improve diagnosis of cardiovascular diseases and prediction of cardiovascular risk by ana...
Financiado
Financiado
PREDICT-IV: Profiling the toxicity of new drugs a non animal based approach integrating toxicodynamics and biok...
EMERGENTEC BIODEVELOPMENT GMBH
participó en un
FP7:
The overall aim of Predict-IV is to develop strategies to improve the assessment of drug safety in the early stage of development and late d...
Financiado
Financiado
OCTIPS: Ovarian Cancer Therapy Innovative Models Prolong Survival
EMERGENTEC BIODEVELOPMENT GMBH
participó en un
FP7:
"About 75% of advanced epithelial ovarian cancer (EOC) patients respond to first-line surgery and chemotherapy but most relapse and ultimate...
Financiado
Financiado
DIPROMON: Multimodular biomarker analysis workflow for diagnosis prognosis and monitoring of drug treatment...
EMERGENTEC BIODEVELOPMENT GMBH
participó en un
FP7:
"With the advent of Omics technologies capable of profiling substantial fractions of molecular entities from the genome down to the metabolo...
Financiado
Financiado
* No se disponen de datos de la empresa actual.